Showing results (1-10 of 198) with videos related to
Sort By:
Pageof 20
Science Translational Medicine|May 4, 2018
ER stress in prostate cancer: A therapeutically exploitable vulnerability?Christopher Logothetis, Ana Aparicio, Timothy C ThompsonCancer|October 10, 2006
Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-alpha-2b: results of a randomized phase II trial of low-dose versus intermediate-dose interferon-alpha-2b in patients with metastatic renal cell carcinomaNizar M Tannir, Lorenzo Cohen, Xuemei Wang, et al.Pathology|December 23, 2019
Epigenetics and prostate cancer: defining the timing of DNA methyltransferase deregulation during prostate cancer progressionVasiliki Tzelepi, Souzana Logotheti, Eleni Efstathiou, et al.Oncology (Williston Park, N.Y.)|July 11, 2002
Docetaxel in the management of advanced or metastatic urothelial tract cancerChristopher Logothetis, Randall MillikanInternational Journal of Cancer|October 23, 2008
Targeting Src signaling in metastatic bone diseaseJohn Araujo, Christopher LogothetisCancer Treatment Reviews|March 16, 2010
Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumorsJohn Araujo, Christopher LogothetisClinical Lung Cancer|April 28, 2006
The potential of histone deacetylase inhibitors in lung cancerAna AparicioClinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 15, 2014
Aggressive variants of castration-resistant prostate cancerHimisha Beltran, Scott Tomlins, Ana Aparicio, et al.Oncology (Williston Park, N.Y.)|October 18, 2014
Neuroendocrine (small-cell) carcinomas: why they teach us essential lessons about prostate cancerAna Aparicio, Vassiliki TzelepiCurrent Opinion in Investigational Drugs (London, England : 2000)|July 2, 2002
Review of the clinical experience with 5-azacytidine and 5-aza-2'-deoxycytidine in solid tumorsAna Aparicio, Jeffrey S WeberPageof 20